NR2F6 and ovarian carcinoma: While we were the first group to identify a role for EAR2 in AML [32], other groups have since shown that EAR-2 is upregulated in breast cancer [33], colorectal cancer [34], cervical cancer [35], ovarian cancer [36] and bladder cancer [37].